BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Kyowa Hakko Release: Submission of New Drug Application for Istradefylline(KW-6002), an Investigational Anti-Parkinson's Disease Drug


4/27/2007 11:42:11 AM

TOKYO, April 26 /PRNewswire-FirstCall/ -- Kyowa Hakko Kogyo Co., Ltd. (President: Dr. Yuzuru Matsuda) announced that Kyowa Pharmaceutical, Inc. (New Jersey, United States, President: Shigeru Kobayashi), its wholly owned U.S subsidiary, submitted on April 25, 2007 a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Istradefylline(KW-6002), its investigational drug for Parkinson's disease.

Parkinson's disease is a progressive neurodegenerative disorder which is characterized by motor symptoms such as slowness of movement, rigidity, tremor and postural instability. The symptoms of this disease result from the progressive degeneration of certain nerve cells located in a specific area in the brain leading to a shortage of the neurotransmitter dopamine. This results in decreased activation of dopamine receptors in the brain which is thought to cause the motor symptoms. The symptoms of Parkinson's disease are treated primarily by dopamine replacement therapy with Levodopa or dopamine agonists. Long term therapy with Levodopa is associated with motor complications such as the development of a shortening response to each dose, which is called "wearing-off phenomenon", and involuntary movements.

Phase II and III clinical studies were conducted with Istradefylline (KW- 6002) in Parkinson's disease patients experiencing "wearing-off phenomenon" on treatment with Levodopa alone or Levodopa administered concomitantly with other Parkinson's disease medications. Based on the clinical efficacy and safety data obtained, the company submitted a NDA for Istradefylline(KW-6002) as adjunctive therapy to levodopa/carbidopa for the treatment of idiopathic Parkinson's disease to improve motor function in patients who experience motor response complications.

Istradefylline(KW-6002) is a novel investigational anti-Parkinson's drug that has a specific antagonistic action on the Adenosine A2A receptor in the brain and is expected to provide benefit to patients with Parkinson's disease.

Contact: TETSURO KUGA, Public Relations Kyowa Hakko Kogyo Co., Ltd. 1-6-1, Ohtemachi, Chiyoda-ku, Tokyo, Japan 100-8185 TEL: +81-3-3282-1903 Fax: +81-3-3282-0990 e-Mail: info@kyowa.co.jp URL: http://www.kyowa.co.jp/eng/index.htm

Kyowa Hakko Kogyo Co., Ltd.

CONTACT: Tetsuro Kuga, Public Relations, Kyowa Hakko Kogyo,+81-3-3282-1903, Fax: +81-3-3282-0990, info@kyowa.co.jp



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES